Oil rebounds from sell-off

GSK, the British pharma group, has struck a $1.4bn deal to acquire Anglo-American biotech Aiolos Bio, which makes respiratory medicines.

The acquisition will give GSK access to a treatment entering mid-stage trials that it hopes will broaden its range of asthma products.

Tony Wood, chief scientific officer at GSK, said that Aiolos’ AIO-001 treatment could “expand the reach of our current respiratory biologics portfolio, including to the 40 per cent of severe asthma patients . . . where treatment options are still needed”.

The deal comes as pharmaceutical companies gather in San Francisco for an annual industry conference, with GSK rivals Johnson & Johnson, Novartis and Merck announcing acquisitions on Monday.

Via

Leave a Comment

cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls cls